These are indicated for treating BRAF mutation cancers, including unresectable or metastatic cutaneous melanoma, metastatic non-small-cell lung cancer, metastatic anaplastic, thyroid cancer, and metastatic colorectal cancer [86,87,88]. Here, BRAF is linked to thyroid gland carcinoma.